242 related articles for article (PubMed ID: 14624186)
1. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.
Arias B; Catalán R; Gastó C; Gutiérrez B; Fañanás L
J Clin Psychopharmacol; 2003 Dec; 23(6):563-7. PubMed ID: 14624186
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram.
Arias B; Catalán R; Gastó C; Gutiérrez B; Fañanás L
J Psychopharmacol; 2005 Mar; 19(2):166-72. PubMed ID: 15728438
[TBL] [Abstract][Full Text] [Related]
3. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
[TBL] [Abstract][Full Text] [Related]
4. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes.
Mitjans M; Gastó C; Catalán R; Fañanás L; Arias B
J Psychopharmacol; 2012 Oct; 26(10):1391-8. PubMed ID: 22826533
[TBL] [Abstract][Full Text] [Related]
6. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
[TBL] [Abstract][Full Text] [Related]
7. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
[TBL] [Abstract][Full Text] [Related]
9. A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder.
Willeit M; Praschak-Rieder N; Neumeister A; Zill P; Leisch F; Stastny J; Hilger E; Thierry N; Konstantinidis A; Winkler D; Fuchs K; Sieghart W; Aschauer H; Ackenheil M; Bondy B; Kasper S
Mol Psychiatry; 2003 Nov; 8(11):942-6. PubMed ID: 14593433
[TBL] [Abstract][Full Text] [Related]
10. SLC6A4 variation and citalopram response.
Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
[TBL] [Abstract][Full Text] [Related]
11. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
[TBL] [Abstract][Full Text] [Related]
12. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.
Putzhammer A; Schoeler A; Rohrmeier T; Sand P; Hajak G; Eichhammer P
Psychopharmacology (Berl); 2005 Mar; 178(2-3):303-8. PubMed ID: 15322730
[TBL] [Abstract][Full Text] [Related]
13. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI).
Eichhammer P; Langguth B; Wiegand R; Kharraz A; Frick U; Hajak G
Psychopharmacology (Berl); 2003 Mar; 166(3):294-7. PubMed ID: 12563545
[TBL] [Abstract][Full Text] [Related]
14. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
[TBL] [Abstract][Full Text] [Related]
15. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.
Durham LK; Webb SM; Milos PM; Clary CM; Seymour AB
Psychopharmacology (Berl); 2004 Aug; 174(4):525-9. PubMed ID: 12955294
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
17. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion.
Moreno FA; Rowe DC; Kaiser B; Chase D; Michaels T; Gelernter J; Delgado PL
Mol Psychiatry; 2002; 7(2):213-6. PubMed ID: 11840315
[TBL] [Abstract][Full Text] [Related]
18. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors.
Arias B; Serretti A; Mandelli L; Gastó C; Catalán R; Ronchi DD; Fañanás L
Pharmacogenet Genomics; 2009 Feb; 19(2):121-8. PubMed ID: 19065121
[TBL] [Abstract][Full Text] [Related]
19. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.
Mitjans M; Serretti A; Fabbri C; Gastó C; Catalán R; Fañanás L; Arias B
Psychopharmacology (Berl); 2013 Jun; 227(3):509-19. PubMed ID: 23407780
[TBL] [Abstract][Full Text] [Related]
20. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases.
Capozzo MA; Schillani G; Aguglia E; De Vanna M; Grassi L; Conte MA; Giraldi T
Tumori; 2009; 95(4):479-83. PubMed ID: 19856660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
